NICHI-IKO PHARMACEUTICAL CO., LTD.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1965-01-01
- Employees
- 2.6K
- Market Cap
- -
- Website
- http://www.nichiiko.co.jp
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
- Target Recruit Count
- 683
- Registration Number
- NCT02990806
- Locations
- π¬π§
Nichi-Iko Investigational Site, Truro, United Kingdom
Pharmacokinetics Study of NI-071
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: InfliximabBiological: NI-071
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT01931189
- Locations
- π―π΅
NichiIko Investigational Site, Tokyo, Japan
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: NI-071Biological: Infliximab
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
- Target Recruit Count
- 242
- Registration Number
- NCT01927263
- Locations
- π―π΅
NichiIko Investigational Site, Sendai-Shi, Japan
Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT01567358
- Locations
- π―π΅
392001001, Sendai, Miyagi, Japan
Β© Copyright 2025. All Rights Reserved by MedPath